Foghorn Therapeutics Inc. Other Income and Expense
Foghorn Therapeutics Inc. (FHTX) reported Other Income and Expense of $1.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-06
- Foghorn Therapeutics Inc. nonoperating income (expense) for the quarter ending 2026-06-30 was $1.61M, a 48.94% decline year-over-year.
- Foghorn Therapeutics Inc. nonoperating income (expense) for the quarter ending 2026-03-31 was $1.70M, a 58.37% decline year-over-year.
- Foghorn Therapeutics Inc. nonoperating income (expense) for the quarter ending 2025-12-31 was $2.21M, a 50.82% decline year-over-year.
- Foghorn Therapeutics Inc. nonoperating income (expense) for the quarter ending 2025-09-30 was $2.65M, a 43.93% decline year-over-year.
- Foghorn Therapeutics Inc. nonoperating income (expense) for fiscal 2025 was $12.11M, a 24.63% decline from fiscal 2024.
- Foghorn Therapeutics Inc. nonoperating income (expense) for fiscal 2024 was $16.06M, a 17.20% increase from fiscal 2023.
- Foghorn Therapeutics Inc. nonoperating income (expense) for fiscal 2023 was $13.71M, a 66.03% increase from fiscal 2022.
- Foghorn Therapeutics Inc. nonoperating income (expense) for fiscal 2022 was $8.26M.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.61M 10-Q · filed 2026-08-06 | $3.31M 10-Q · filed 2026-08-06 | $5.53M derived: sum of 3 quarters · filed 2026-08-06 | $8.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.70M 10-Q · filed 2026-05-07 | $3.91M derived: sum of 2 quarters · filed 2026-05-07 | $6.56M derived: sum of 3 quarters · filed 2026-05-07 | $9.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $4.87M derived: sum of 2 quarters · filed 2026-03-11 | $8.03M derived: sum of 3 quarters · filed 2026-08-06 | $12.11M 10-K · filed 2026-03-11 |
| 2025-09-30 | $2.65M 10-Q · filed 2025-11-05 | $5.81M derived: sum of 2 quarters · filed 2026-08-06 | $9.89M 10-Q · filed 2025-11-05 | $14.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.16M 10-Q · filed 2026-08-06 | $7.24M 10-Q · filed 2026-08-06 | $11.74M derived: sum of 3 quarters · filed 2026-08-06 | $16.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.08M 10-Q · filed 2026-05-07 | $8.58M derived: sum of 2 quarters · filed 2026-05-07 | $13.31M derived: sum of 3 quarters · filed 2026-05-07 | $16.96M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $9.23M derived: sum of 2 quarters · filed 2026-03-11 | $12.88M derived: sum of 3 quarters · filed 2026-03-11 | $16.06M 10-K · filed 2026-03-11 |
| 2024-09-30 | $4.73M 10-Q · filed 2025-11-05 | $8.38M derived: sum of 2 quarters · filed 2025-11-05 | $11.56M 10-Q · filed 2025-11-05 | $14.90M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $3.65M 10-Q · filed 2025-08-05 | $6.83M 10-Q · filed 2025-08-05 | $10.17M derived: sum of 3 quarters · filed 2025-08-05 | $13.64M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $3.18M 10-Q · filed 2025-05-14 | $6.52M derived: sum of 2 quarters · filed 2025-05-14 | $9.99M derived: sum of 3 quarters · filed 2025-05-14 | $13.49M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $6.81M derived: sum of 2 quarters · filed 2025-03-06 | $10.32M derived: sum of 3 quarters · filed 2025-03-06 | $13.71M 10-K · filed 2025-03-06 |
| 2023-09-30 | $3.47M 10-Q · filed 2024-11-04 | $6.98M derived: sum of 2 quarters · filed 2024-11-04 | $10.37M 10-Q · filed 2024-11-04 | $13.37M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $3.50M 10-Q · filed 2024-08-08 | $6.89M 10-Q · filed 2024-08-08 | $9.89M derived: sum of 3 quarters · filed 2024-08-08 | $12.38M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.39M 10-Q · filed 2024-05-06 | $6.39M derived: sum of 2 quarters · filed 2024-05-06 | $8.88M derived: sum of 3 quarters · filed 2024-05-06 | $10.75M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $5.49M derived: sum of 2 quarters · filed 2024-03-07 | $7.37M derived: sum of 3 quarters · filed 2024-03-07 | $8.26M 10-K · filed 2024-03-07 |
| 2022-09-30 | $2.49M 10-Q · filed 2023-11-02 | $4.37M derived: sum of 2 quarters · filed 2023-11-02 | $5.25M 10-Q · filed 2023-11-02 | $4.19M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $1.88M 10-Q · filed 2023-08-04 | $2.77M 10-Q · filed 2023-08-04 | $1.70M derived: sum of 3 quarters · filed 2023-08-04 | $1.89M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $890.00K 10-Q · filed 2023-05-08 | -$171.00K derived: sum of 2 quarters · filed 2023-05-08 | $10.00K derived: sum of 3 quarters · filed 2023-05-08 | $160.00K derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$880.00K derived: sum of 2 quarters · filed 2023-03-09 | -$730.00K derived: sum of 3 quarters · filed 2023-03-09 | -$586.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $181.00K 10-Q · filed 2022-11-08 | $331.00K derived: sum of 2 quarters · filed 2022-11-08 | $475.00K 10-Q · filed 2022-11-08 | $496.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $150.00K 10-Q · filed 2022-08-09 | $294.00K 10-Q · filed 2022-08-09 | $315.00K derived: sum of 3 quarters · filed 2022-08-09 | $437.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $144.00K 10-Q · filed 2022-05-09 | $165.00K derived: sum of 2 quarters · filed 2022-08-09 | $287.00K derived: sum of 3 quarters · filed 2022-08-09 | $103.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $21.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $143.00K derived: sum of 2 quarters · filed 2022-08-09 | -$41.00K derived: sum of 3 quarters · filed 2022-08-09 | -$269.00K 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $122.00K 10-Q · filed 2021-11-09 | -$62.00K derived: sum of 2 quarters · filed 2021-11-09 | -$290.00K 10-Q · filed 2021-11-09 | -$396.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$184.00K 10-Q · filed 2021-08-10 | -$412.00K 10-Q · filed 2021-08-10 | -$518.00K derived: sum of 3 quarters · filed 2021-08-10 | -$510.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$228.00K 10-Q · filed 2021-05-11 | -$334.00K derived: sum of 2 quarters · filed 2021-05-11 | -$326.00K derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | -$106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$98.00K derived: sum of 2 quarters · filed 2021-03-18 | -$44.00K 10-K · filed 2021-03-18 | |
| 2019-09-30 | $8.00K 10-Q · filed 2020-12-04 | $62.00K 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |